Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
Asad Haider is recorded as Analyst at Goldman Sachs. Asad Haider has spoken on 10 earnings calls and 1 other investor event across 7 companies, most recently for Bristol Myers Squibb Co on July 30, 2026. Those appearances were for Bristol Myers Squibb Co (BMY), Johnson & Johnson (JNJ), ELI LILLY & Co (LLY), Royalty Pharma plc (RPRX), Pfizer Inc (PFE) and 2 other companies. The companies whose calls Asad Haider spoke on are classified in the Healthcare sector.
“Maybe for Christian on animal parent, this now seems to be becoming the key clinical event for the balance of the year given the updates that you guys just described.”
“Maybe for Jennifer, John, and Iketide, just the launch seems to be progressing well. You noted 10,000 patients have now initiated therapy. Just wondering if you can provide any update on prescriber count relative to the last update of 4,500 prescribers that you called out in June.”
“I'm the co-head of the Healthcare Research Business Unit at Goldman Sachs. I'm also the U.S. Pharma Analyst. I'm very pleased to open the conference with Dr. Albert Bula, CEO of Pfizer.”
“Maybe just to open, just given how consequential the clinical readouts at the end of this year are going to be for the company, Christian, just starting with you, can you just level set us on your confidence in the key programs, specifically for Milvexian AF and the Cobenphia DEP trials, just any quantitative bars for…”
Goldman Sachs
Analyst
Source not stated
Drug Manufacturers - General · Healthcare
Drug Manufacturers - General · Healthcare
LLY
Drug Manufacturers - General · Healthcare
RPRX
Biotechnology · Healthcare
PFE
Drug Manufacturers - General · Healthcare
BNTX
Biotechnology · Healthcare
ABBV
Drug Manufacturers - General · Healthcare
